Mylan Stock Remains Lower Amid Scrutiny of EpiPen Pricing: Chart

(Bloomberg) -- Mylan NV fell for a third day after U.S. senators scrutinized pricing of the drugmaker’s EpiPen emergency allergy shot following a more than 400 percent increase in its cost. Two injections of the self-administered epinephrine now run more than $600, according to prescription drug-price tracker GoodRx. In an Aug. 22 letter, Chuck Grassley, chairman of the Senate Committee on the Judiciary, asked Mylan to explain the “substantial price increase.”

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net. To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Sophie Caronello at scaronello@bloomberg.net, Nancy Moran